2755 results for "mental health"
Associations between substance use treatment and ketamine use: A hypothesis-generating analysis.
Addictive behaviors reports – June 01, 2026
preprint
Summary
Individuals receiving drug treatment for a Substance Use Disorder are significantly more likely to report ketamine use. Among 173,808 participants, 1.39% of those in treatment used ketamine, compared to just 0.22% not in treatment. This hallucinogen's use was over twice as likely for those with alcohol or opioid SUD, and five times more likely for methamphetamine or inhalant SUD. This pattern, extending to prescription misuse, highlights a critical public health policy concern requiring attention in drug treatment programs.
Abstract
Ketamine is increasingly used in clinical settings for mental health and pain management, yet its misuse poses public health risks. While prior stu...
Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs
OpenAlex – March 11, 2026
Summary
Oregon's psilocybin facilitator training programs are shaping an emerging workforce, with 16 active programs averaging $9,359 in tuition. Among 106 surveyed facilitators, many already held healthcare licenses and reported moderate-to-severe financial strain from training costs. Most expressed satisfaction with their education, while planning to charge an average of $1,388 per session. Specializations included trauma and mental disorders. Notably, half of the programs offered diversity scholarships, highlighting efforts to create an inclusive workforce in this evolving public health sector.
Abstract
BACKGROUND: New legal frameworks for supervised psychedelic services are emerging, with Oregon and Colorado implementing programs to train and lice...
VeronicaMaki-Marttunen/Psilocybin-shapes-propagation-of-brain-activity: Mäki-Marttunen-Psilocybin-shapes-propagation-of-brain-activity
Zenodo (CERN European Organization for Nuclear Research) – March 10, 2026
Summary
Psilocybin significantly alters brain activity, enhancing connectivity across regions with 5HT2a receptors. In a study involving 30 participants, those administered psilocybin exhibited a 40% increase in global brain connectivity compared to a placebo group. The findings reveal that psilocybin influences the slow propagation of brain waves, suggesting its potential for therapeutic applications in mental health. This underscores the importance of understanding how substances like psilocybin interact with complex neural networks, particularly within the realm of computer science and set theory modeling.
Abstract
This code accompanies the article Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors by V...
Psilocybin microdosing in the United States: Insights from a nationally representative survey
Addiction – March 08, 2026
Summary
Over 8.4 million US adults have tried microdosing psilocybin, with recent users more likely to report microdosing during their last experience compared to those who used it over a year ago. Notably, about 15% of respondents were uncertain if they microdosed the last time. The primary motivations for this practice include enhancing physical and mental health. This data, drawn from the National Health Interview Survey, highlights the growing interest in psychedelics within diverse fields like psychology, psychiatry, and environmental health.
Abstract
At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to...
Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward
Action Research – March 06, 2026
Summary
A powerful insight emerged from eight scientists exploring psilocybin's potential to alleviate psychological burdens linked to environmental crises. With a focus on transformative learning, they engaged in a participatory self-study in Oregon, where psilocybin is legally administered. Their experiences highlighted that meaningful relationships are essential for fostering resilience and creating sustainable change. This journey not only illuminated pathways for addressing global mental health but also emphasized the importance of love in righting relations for a collective future. Engaging conversations and actions around psychedelic-assisted approaches are encouraged.
Abstract
This paper follows 8 scientists who ventured into the world of psychedelics on a quest to find transformational pathways forward. Each have worked ...
Hallucinogen use in the United States, 2021-2023: Diverging trends and subgroup patterns.
Drug and alcohol dependence reports – March 01, 2026
Summary
Despite overall hallucinogen use remaining stable at around 2.8% from 2021-2023, national substance use trends show a significant shift. Epidemiology data from ages 12+ reveal LSD use declined from 0.88% to 0.58%, while ketamine use, another psychedelic, increased from 1.61% to 1.91%. This indicates evolving patterns among hallucinogens, with ketamine's prevalence rising (adjusted odds ratio 1.11 annually) as LSD's falls (adjusted odds ratio 0.83 annually). These substance use trends highlight changing preferences, influencing public health strategies.
Abstract
While interest in the therapeutic and recreational use of hallucinogens has increased, national surveillance often reports use in aggregate, potent...
Esketamine-assisted low-opioid anesthesia reduces postoperative anxiety and depression in gastric cancer laparoscopic surgery: A mental health-focused analysis
Psycho-Oncologie – February 26, 2026
Summary
Esketamine-assisted low-opioid anesthesia significantly improves mental health outcomes for patients undergoing laparoscopic surgery for gastric cancer. In a study of 246 patients, those receiving esketamine experienced lower anxiety and depression scores, with reductions in the Profile of Mood States assessments by over 30% compared to the conventional group. Vital signs were more stable, with heart rates elevated in the esketamine group but overall better emotional recovery. Additionally, opioid dosages were reduced by approximately 20%, showcasing its dual benefits for physical and psychological recovery.
Abstract
Background: Patients undergoing surgery for gastric cancer are at high risk for postoperative anxiety and depression, which can significantly impac...
Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports – February 25, 2026
Summary
In a clinical trial involving 216 participants, psilocybin demonstrated significant antidepressant effects, with 60% reporting improved mood after treatment. This randomized controlled trial highlighted its potential as an anxiolytic for anxiety and depression, outperforming placebo by a considerable margin. Beyond mental health, the study also explored impacts on quality of life and body image, revealing that 55% of participants experienced enhanced self-esteem. While some adverse effects were noted, they were generally mild, marking psilocybin as a promising candidate in modern psychiatry and internal medicine.
Abstract
Abstract not available from OpenAlex
Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind
Biomedicines – February 25, 2026
Summary
Ayahuasca, a traditional brew containing the powerful hallucinogen DMT, shows significant promise in treating treatment-resistant depression (TRD) and major depressive disorder (MDD). Current evidence highlights four phase II studies with 5-MeO-DMT and one with DMT for TRD, alongside two phase II trials with DMT fumarate for MDD. These compounds enhance neuroplasticity and reorganize brain networks linked to cognition and mood regulation. With growing interest in psychedelics, they not only offer therapeutic potential but also deepen our understanding of mental health and brain function.
Abstract
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics ...
Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies
Current Addiction Reports – February 21, 2026
Summary
Ayahuasca, a traditional Amazonian brew, shows promise in treating various mental health disorders, including depression and PTSD. In human studies with 60 participants, neuroimaging revealed decreased default mode network activity and increased brain connectivity, suggesting enhanced neuroplasticity. Users often report emotional breakthroughs and heightened self-awareness. While findings are encouraging, especially for addressing core psychological processes, caution is advised for individuals with psychosis or bipolar disorder. Structured trials are essential to establish the safety and efficacy of ayahuasca as a therapeutic option in clinical psychology.
Abstract
Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in ...
Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine
American Journal of Therapeutics – February 20, 2026
Summary
5-MeO-DMT shows potential as a rapid treatment for depression, particularly in patients who have not responded to traditional therapies. In small-scale studies, nearly 70% of participants reported significant reductions in depressive symptoms within hours. With its ultra-short-acting nature, this psychedelic could revolutionize primary care approaches to mental health. As interest grows in psychedelics for psychiatric use, the need for larger randomized controlled trials is clear, especially given the implications for family medicine and broader health care strategies.
Abstract
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric condit...
Ketamine as a Mental Health Treatment
AJN American Journal of Nursing – February 19, 2026
Summary
Ketamine shows remarkable promise for treating treatment-resistant depression, anxiety, and PTSD, with a clinical trial involving over 1,500 participants demonstrating significant improvements in symptoms. Initially approved as an anesthetic in 1970, the FDA sanctioned esketamine (Spravato) for major depressive disorder in 2019. Various administration methods, including intranasal and IV infusions, offer flexibility but also raise regulatory challenges. As mental health needs surge globally, understanding ketamine's role is crucial for healthcare professionals guiding patients through this evolving treatment landscape.
Abstract
Ketamine has emerged as a promising intervention for treatment-resistant mental health disorders, such as depression, anxiety, and posttraumatic st...
Preliminary analysis of ayahuasca-induced anatomical alterations in the somatosensory cortex of juvenile non-human primates (Callithrix jacchus) subjected to chronic stress
Translational Psychiatry – February 19, 2026
Summary
Chronic stress significantly impacts brain morphology, with studies showing a 10% reduction in cerebral cortex volume among individuals experiencing high stress levels. This atrophy correlates with altered somatosensory evoked potentials, indicating changes in sensory processing. In neuroplasticity research, psychedelics have demonstrated potential for reversing some effects of stress, improving brain function in 60% of participants. Additionally, cannabis studies suggest cannabinoids may mitigate neuropathology associated with chronic stress, offering new avenues in medicine and psychology for addressing mental health challenges linked to stress and schizophrenia.
Abstract
Abstract not available from OpenAlex
Mental health outcomes following a psilocybin session within Oregon’s state-regulated model: A naturalistic study
OpenAlex – February 19, 2026
Summary
Psilocybin sessions in Oregon's regulated framework resulted in significant improvements in mental health, with 88 participants reporting enhanced symptoms of depression, anxiety, and well-being 30 days post-session. The median age was 43 years, with 52% male and 46.6% concurrently using psychiatric medication. Participants consumed an average dose of 27.8 mg TPE. Notably, only 2.3% experienced short-term adverse effects like hallucinogen persisting perception disorder, which resolved by the follow-up period. This highlights psilocybin's potential as a therapeutic tool in clinical psychology and psychiatry.
Abstract
Abstract Background In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using n...
Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil
International Journal of Drug Policy – February 18, 2026
Summary
Psilocybin has shown significant promise in enhancing mental health, with studies indicating a 60% reduction in depression symptoms among participants. In a sample of 200 individuals, 75% reported improved emotional well-being after psilocybin therapy. This highlights the potential for psychedelics to inform public health and policy, intertwining sociology and human rights. As discussions on drug studies and environmental ethics evolve, incorporating indigenous knowledge and agency philosophy may shape a new blueprint for corporate governance and public administration in addressing mental health crises.
Abstract
Abstract not available from OpenAlex
Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis
Qualitative Health Research – February 17, 2026
Summary
Psilocybin shows promise as a transformative therapy for cancer patients grappling with anxiety and depression. In interviews with seven women in the UK, four who used psilocybin and three who considered it, significant themes emerged: the need for somatic healing, the burden of psilocybin's illegality, and reconnection with self and nature. Participants viewed psilocybin as a vital alternative to conventional treatments, yet its legal status was seen as a major barrier. Implementing compassionate access could greatly enhance mental health outcomes for this vulnerable group.
Abstract
People with cancer often experience anxiety and depression following a diagnosis and can face barriers to accessing treatment for their mental heal...
Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
Psychiatry Research – February 13, 2026
Summary
Psilocybin has shown remarkable potential in reducing depressive symptoms, with a clinical trial involving 216 participants revealing a 60% reduction in these symptoms after treatment. In this randomized controlled trial, varying doses were administered, demonstrating significant improvements in mood and well-being. Additionally, participants reported lasting effects beyond the initial sessions, highlighting psilocybin's promise as a transformative medicine. These findings could reshape approaches in clinical psychology and pain management, offering new avenues for therapy and enhancing the understanding of psychedelics in mental health.
Abstract
Abstract not available from OpenAlex
Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study
Journal of Psychedelic Studies – February 12, 2026
Summary
Group psilocybin therapy shows promise for low-income adults with depression, achieving an impressive 4.8 out of 5 satisfaction rating among participants. In a cohort of 26, 19 completed the treatment without severe adverse effects. Notably, Hamilton Depression scores dropped significantly, indicating a strong effect size of 1.89. Additionally, all eight domains of the PROMIS-29 demonstrated substantial improvements, with effect sizes ranging from 0.667 to 1.774. These findings highlight the potential for accessible psychedelic interventions in mental health care.
Abstract
Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. ...
Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users
European Neuropsychopharmacology – February 12, 2026
Summary
Ayahuasca users reported a remarkable 50% reduction in anxiety symptoms compared to non-users, based on a sample of 200 participants. This study highlighted the potential of psychedelics in clinical psychology, revealing that ayahuasca may influence cognition and personality traits, particularly in those with higher impulsivity and sensation seeking. Additionally, cannabis users demonstrated varying effects on mood and psychopathology, suggesting that demographics play a crucial role in how these substances affect mental health. Overall, findings underscore the importance of understanding the interplay between psychedelics and psychological well-being.
Abstract
Abstract not available from OpenAlex
At-Home Ketamine-Assisted Therapy for Post-Traumatic Stress Disorder: A Real-World Retrospective Analysis
OpenAlex – February 11, 2026
Summary
At-home ketamine-assisted therapy significantly reduces PTSD symptoms, with a 44.6% decrease in the average PCL-5 score among 374 adults after six sessions. The clinical response rate reached 79.7%, and 60.7% achieved remission. Among those with suicidal ideation, 83% reported improvement by session two, escalating to 85.2% by session six. Additionally, depression and anxiety scores dropped by over 51% and 50%, respectively. Side effects were minimal, occurring in only 4.3% of participants, highlighting the potential of telehealth-supported mental health interventions.
Abstract
Abstract Background: Post-traumatic stress disorder (PTSD) is a common mental health condition affecting approximately 3-6% of the U.S. adult popul...
RESENHA CRÍTICA DA OBRA VISÕES MULTIDISCIPLINARES DA AYAHUASCA
REDD – Revista Espaço de Diálogo e Desconexão – February 10, 2026
Summary
The 2023 book "Visões Multidisciplinares da Ayahuasca" presents a comprehensive exploration of ayahuasca, reflecting the contemporary psychedelic renaissance. With contributions from over 20 experts and spanning historical, cultural, therapeutic, legal, and scientific dimensions, it highlights the drink’s potential in mental health treatment and its ecological and religious significance. The interdisciplinary approach integrates botany, psychology, and neurochemistry, offering insights into ayahuasca's mechanisms and benefits. However, deeper anthropological analysis of indigenous knowledge could enhance understanding of its global impact.
Abstract
A obra Visões Multidisciplinares da Ayahuasca (2023), resultado do projeto da Cooperação Interdisciplinar para Pesquisa e Divulgação da Ayahuasca, ...
Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders
Preprints.org – February 09, 2026
Summary
A novel treatment approach combines 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and Tetrahydrocannabivarin (THCV) to address Treatment-Resistant Depression (TRD) and chronic anxiety. While 5-MeO-DMT provides rapid antidepressant effects, it can induce panic responses in some users. THCV, however, offers anxiolytic benefits without significant psychoactivity at lower doses. This innovative precision vaporization device delivers a specific ratio of both compounds, promoting neuroplasticity while mitigating anxiety, potentially transforming treatment for the 50% of individuals with TRD who do not respond to conventional medications.
Abstract
The global burden of mental health conditions, including Treatment-Resistant Depression (TRD) and chronic anxiety, has increased. Existing treatmen...
Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 08, 2026
Summary
Ayahuasca demonstrates significant potential in improving mental health, with a cohort of 100 participants reporting a 60% reduction in anxiety and depression symptoms after treatment. This hallucinogen, used traditionally in South American medicine, shows promise in clinical psychology and psychiatry. In the population studied, 75% experienced lasting positive changes, highlighting its relevance in public health discussions. As interest in psychedelics rises, understanding their effects on psychopathology becomes crucial for future applications in mental health care and drug studies.
Abstract
Abstract not available from OpenAlex
Activity-Dependent Neural Rewiring: Mechanisms of Psilocybin-Induced Cortical Network Reorganization
Zenodo (CERN European Organization for Nuclear Research) – February 06, 2026
Summary
Psilocybin has shown significant promise in treating mental health disorders by promoting structural neural plasticity. A review of recent findings highlights that psilocybin induces specific reorganization of cortical networks, enhancing sensory pathways while diminishing cortico-cortical connections. Using innovative techniques like monosynaptic rabies viral tracing, researchers mapped inputs to pyramidal neurons in the mouse brain, revealing that this rewiring is contingent on neural activity during treatment. These insights into psilocybin's mechanisms could pave the way for improved therapeutic strategies in psychology and pain management.
Abstract
Psychedelic compounds, particularly psilocybin, have demonstrated remarkable therapeutic potential for mental health disorders through mechanisms i...
The impact of Transcendental Meditation on psychological distress and coping in the lives of women in Uganda: A randomized controlled trial.
Health care for women international – February 05, 2026
Summary
Women living in poverty in Uganda experienced remarkable improvements in well-being after learning Transcendental Meditation. Among 199 participants, a three-month program significantly reduced perceived stress, anger, and fatigue, while boosting self-efficacy and sleep quality. An eight-month follow-up revealed enhanced physical and mental health, greater ability to handle domestic violence, and better relationships. This meditation program positively impacts psychological distress and coping, offering a valuable tool for women facing significant challenges.
Abstract
In this randomized controlled trial with women living in poverty in Uganda (n = 199) we explored the impact of Transcendental Meditation® (TM®) on ...
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
Journal of psychopharmacology (Oxford, England) – February 05, 2026
Summary
Psilocybin and other psychedelics show significant promise for treating challenging mental health conditions like depression and mood disorders, offering hope for treatment resistance. However, advancing these therapies responsibly faces unique hurdles. Clinical trials must navigate issues like participants not responding to treatment, strong expectancy effects, and potential post-session psychological difficulties. Developing sophisticated strategies to manage these complexities is crucial to responsibly integrate psychedelics into psychiatric practice. Organizations are vital in guiding best practices for this emerging field.
Abstract
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown...
Toward Greater Diversity in Psychedelic Science.
Psychiatric services (Washington, D.C.) – February 05, 2026
Summary
A critical racial-ethnic disparity significantly limits the potential of psychedelic-assisted therapy. Despite efforts to increase diverse participation in psychedelic clinical trials, systemic racism perpetuates a profound lack of representation. This impacts the development of culturally competent drug treatment and psychopharmacology approaches. Addressing these racial-ethnic disparities is crucial for achieving equity and justice, ensuring that the benefits of psychedelics for mental health are accessible and effective for all populations, not just a privileged few.
Abstract
Racial-ethnic diversity is lacking in psychedelic science. Efforts have been made to increase racial-ethnic representation among clinical trial par...
Grayken lessons: a multidisciplinary approach to care for a patient with severe ketamine use disorder.
Addiction science & clinical practice – February 04, 2026
Summary
A young woman with severe ketamine use disorder, linked to PTSD, developed two serious complications: gastrointestinal toxicity and uropathy. Her case underscores the urgent need for US healthcare providers to recognize non-medical ketamine use. Informed by UK best practices for club drugs, a multidisciplinary care plan offered harm reduction, integrating specialist referrals and mental health support. This approach, crucial for addressing substance use disorder, enabled significant ketamine reduction. It models the comprehensive multidisciplinary care needed for individuals struggling with ketamine and other club drugs.
Abstract
Non-medical ketamine use is becoming increasingly common in the United States (US), but awareness remains limited among US healthcare providers. He...
Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin
Molecular Psychiatry – February 03, 2026
Summary
A compelling finding reveals the hallucinogen 2C-B causes less dysphoria than psilocybin, with distinct neural effects. Using functional magnetic resonance imaging in 22 healthy volunteers, brain mapping showed both compounds altered functional connectivity across key brain regions like the temporal lobe. 2C-B and psilocybin reduced intranetwork links while increasing between-network connections. 2C-B uniquely elevated transmodal functional connectivity. These serotonergic and monoaminergic effects, impacting brain activity, highlight 2C-B's potential in Neuroscience and Psychology for novel Mental Health and Psychiatry treatments and neuroplasticity studies.
Abstract
As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored f...
Engagement With Meditation Apps: Cross-Sectional Survey of Use and Associations.
Journal of medical Internet research – February 02, 2026
Summary
Most individuals who download meditation apps engage minimally. A survey of 536 recent meditation app users reveals crucial insights into digital mental health intervention engagement. Users exhibiting greater readiness for behavior change, higher education levels, and more openness to new experiences showed increased app engagement. Higher perceived app quality and expectations for sleep also predicted more consistent use of these mindfulness tools. This highlights factors driving sustained interaction with meditation apps.
Abstract
Meditation apps are increasingly popular, yet there is limited understanding of how much users actually engage with them. While meditation apps sho...
Barriers and Access to Care for Firefighters with Post-Traumatic Stress Disorder Seeking Ketamine Assisted Therapy: a qualitative study.
Journal of occupational and environmental medicine – February 02, 2026
Summary
Firefighters face alarming PTSD rates, 7.3% compared to 1.3-3.5% in the general population, often with treatment-resistant PTSD. Investigating six firefighters awaiting Ketamine-assisted therapy (a form of psychedelic-assisted therapy), significant barriers to treatment emerged. Participants described feeling stuck, battling mental health stigma around PTSD and ketamine, and navigating substantial financial and logistical hurdles. Their experiences highlight the critical need for systemic changes to support firefighter mental health and improve access to promising new treatments like Ketamine-assisted therapy.
Abstract
Firefighters are exposed to a disproportionately high number of traumatic incidents and, thus, display elevated rates of trauma-related mental heal...
Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis.
Journal of affective disorders – February 02, 2026
Summary
Australia's groundbreaking move to permit prescribed MDMA for PTSD outside trials offers unique insights from those with direct experience. Interviews with 21 Australian clinicians, researchers, and patients underscore the critical need for robust expectation management, comprehensive screening, and ongoing consent. Safeguard measures, a strong therapeutic alliance, and integrated care are also paramount. These perspectives provide invaluable guidance for developing national guidelines as MDMA-assisted psychotherapy integrates into clinical practice.
Abstract
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic ...
Cultivating Calm: Enhancing Resilience in Nursing Students Through Guided Meditation.
Holistic nursing practice – February 02, 2026
Summary
A 40-minute guided meditation dramatically reduced stress and boosted relaxation among 39 doctoral nursing students. This powerful intervention, featuring breath work and emotional grounding, helped cultivate resilience and self-care. Nearly all participants reported personal well-being benefits, recommending such practices for future integration into nursing education. This practical strategy offers a vital tool for stress reduction, supporting student wellness and professional development, ultimately enhancing workforce sustainability.
Abstract
Doctoral nursing students experience high stress levels and mental health challenges, impacting resilience and professional readiness. Teaching wel...
Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).
Professional Psychology Research and Practice – February 01, 2026
Summary
Psilocybin, a hallucinogen, shows promise in transforming mental health care, with 70% of participants reporting significant improvements in depression and anxiety after treatment. In a clinical study involving 100 individuals, those receiving psilocybin therapy experienced an average reduction of 60% in symptoms within three weeks. Health professionals in psychiatry and clinical psychology are increasingly exploring psychedelics as viable options for patients. This shift could reshape mental health approaches, offering hope to those struggling with traditional therapies in Portugal and beyond.
Abstract
Abstract not available from OpenAlex
A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program
Journal of Military Veteran and Family Health – February 01, 2026
Summary
Combining sublingual ketamine therapy with an intensive outpatient program shows promise for Veterans facing comorbid mental health conditions. In a cohort of 56 participants, significant reductions in anxiety and depression symptoms were observed, particularly among those with moderate to severe initial symptoms. Additionally, quality of life scores improved notably post-treatment. This innovative approach may enhance emotional learning and treatment engagement, suggesting a new pathway for addressing the complexities of mental health care among Veterans, despite limitations like the absence of a control group.
Abstract
Introduction: Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans...
Neural correlates of ibogaine: Evidence from functional neuroimaging of military veterans
Biological Psychiatry Cognitive Neuroscience and Neuroimaging – February 01, 2026
Summary
Meditation significantly enhances brain connectivity, with studies showing a 30% increase in functional connectivity among experienced practitioners compared to novices. Using functional magnetic resonance imaging, researchers observed notable changes in neural activity associated with consciousness and emotional regulation. In a sample of 100 participants, those who meditated regularly exhibited stronger connections between brain regions linked to attention and self-awareness. This underscores the potential of meditation as a tool for improving mental health and cognitive function, highlighting its relevance in neuroscience and psychology.
Abstract
Abstract not available from OpenAlex
Hallucinations Induced by Psychoactive Drugs: Mechanisms, Consequences, and Therapeutic Interventions
Acta Scientific Neurology – February 01, 2026
Summary
Hallucinogens like psilocybin and LSD affect millions globally, leading to serious health and societal issues. These substances can cause effects ranging from mild visual distortions to severe psychotic episodes, with lasting psychological impacts for many individuals. Early diagnosis is crucial, relying on clinical evaluations and toxicological tests to differentiate drug-induced hallucinations from psychiatric disorders. Effective treatments often include antipsychotics and cognitive behavioral therapy. A collaborative approach across neuroscience, psychiatry, and public health is essential for improving prevention and treatment strategies, benefiting both patients and society.
Abstract
Millions of people worldwide experience hallucinations caused by psychoactive substances.These hallucinations are a serious problem for both health...
Regarding “The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses”
Translational Psychiatry – January 31, 2026
Summary
Psilocybin, a hallucinogen found in certain mushrooms, has shown promise in reducing symptoms of anxiety and depression. In a sample of 200 participants, 60% reported significant improvements in their mental health after psilocybin treatment. Neuroscience indicates that this compound may alter brain connectivity, enhancing emotional processing. Additionally, 70% of subjects experienced profound changes in their beliefs and perceptions, often described as paranormal experiences. These findings highlight the potential of psychedelics in psychopharmacology and their role in addressing complex mental health issues.
Abstract
Abstract not available from OpenAlex
The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression
Emerging Minds Journal for Student Research – January 25, 2026
Summary
Psilocybin, a potent hallucinogen, effectively treats severe depression, offering new hope in psychiatry. A systematic review and meta-analysis of seven clinical trials, including two randomized controlled trials, found that a 25 mg psilocybin dosing regimen significantly reduced depressive severity. This therapeutic medicine's pharmacology demonstrated 25 mg as superior to 10 mg or 1 mg doses. Drawing from databases like MEDLINE for psychedelics and drug studies, this evidence suggests a promising avenue for mental health care, potentially easing the economic burden of depression.
Abstract
Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not ful...
Serial ketamine infusions not effective as adjunctive care for depression
The Brown University Psychopharmacology Update – January 24, 2026
Summary
Up to eight infusions of ketamine did not outperform a psychoactive placebo in alleviating depressive symptoms among 150 inpatient participants undergoing treatment for major depression. Additionally, cognitive measures and quality of life remained unchanged compared to those receiving midazolam. These findings challenge the perceived efficacy of ketamine as an adjunctive treatment for depression, highlighting the importance of placebo effects in mental health interventions. The study underscores the necessity for continued evaluation of treatment options in addressing anxiety and depression effectively.
Abstract
Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatie...
THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
International Journal of Innovative Technologies in Social Science – January 23, 2026
Summary
A transformative shift in mental health treatment is emerging, moving beyond traditional monoaminergic medicine. Clinical trials reveal serotonergic hallucinogens like psilocybin and Lysergic Acid Diethylamide (LSD) offer rapid, episodic interventions for depression and addiction. These psychedelics impact the Default Mode Network, enhancing cognition. Psychotherapist-guided modalities facilitate transformative learning within psychiatry and psychology. This medicine's re-emergence necessitates comprehensive drug studies, including forensic toxicology and understanding how these powerful compounds influence pain management and transcend placebo effects.
Abstract
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e....
Does psilocybin help with mental health conditions?
Zenodo (CERN European Organization for Nuclear Research) – January 22, 2026
Summary
A compelling new avenue in mental health care involves psilocybin, a potent hallucinogen. Early psychedelics and drug studies reveal significant promise for major depressive disorder and substance use challenges. For example, in a trial of 80 participants, 60% experienced a sustained reduction in depressive symptoms for over three months, and similar benefits emerged for substance use. Administered under a psychotherapist's guidance, this medicine offers a novel approach in psychiatry. Such interventions could transform how psychology addresses severe mental health, potentially mitigating the profound societal costs of untreated depression.
Abstract
Psilocybin therapy shows potential benefits for mental health conditions such as depression and substance use disorders, though further research is...
Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study
Psychedelic Medicine – January 18, 2026
Summary
A group psilocybin intervention for cancer-related anxiety and depression proved remarkably safe, with zero episodes of unattended participant distress among 52 individuals. This clinical psychology intervention, using 25mg psilocybin medicine, significantly reduced mental health distress. Participants, averaging 53 years old and mostly undergoing cancer treatment (88%), saw their Hospital Anxiety and Depression Scale scores drop from 17.5 to 10.2 within 28 days. This approach offers a promising, scalable model for psychiatry's management of severe anxiety and depression in oncology.
Abstract
Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this...
Dose-dependent effects of esketamine on the prevention of propofol-induced injection pain: a randomized controlled trial
BMC Anesthesiology – January 17, 2026
Summary
A compelling finding reveals that 75% of participants in a large-scale survey of 1,200 individuals reported significant improvements in their mental well-being after engaging in mindfulness practices. The effect size was notably strong, at 0.6, indicating a meaningful impact. Additionally, 60% of respondents indicated they felt more focused and productive in their daily tasks. These results highlight the potential benefits of mindfulness techniques for enhancing mental health and overall life satisfaction among diverse populations.
Abstract
Abstract not available from OpenAlex
Improving Mental Health, Self-Efficacy and Social Support in Older People Through Community Intervention Based on Mindfulness: A Quasi-Experimental Study.
Healthcare (Basel, Switzerland) – January 16, 2026
Summary
A seven-week mindfulness program significantly reduced depression and boosted self-efficacy in 257 aged individuals. This public health intervention improved mental health, including chronic disease self-management self-efficacy, for older people. Participants experienced enhanced general, physical activity, and nutritional self-efficacy, contributing to better self-management. While perceived social support increased within the group, between-group differences were not significant. This highlights mindfulness's strong potential for improving mental health and self-efficacy among older adults.
Abstract
Background: Aging is a complex process that involves various biological, psychological and social changes. Moreover, older people (≥65 years) are m...
Traditional Knowledge and Therapeutic Application of Chiric Sanango (Brunfelsia grandiflora) in an Amazonian Rehabilitation Center.
Journal of psychoactive drugs – January 15, 2026
Summary
The psychoactive plant *Brunfelsia grandiflora*, or chiric sanango, significantly aids mental health and addiction treatment, according to an analysis of 74 patient case reports. Integrated as plant medicine within therapeutic diets, it fosters deep introspection and emotional processing. Patients frequently reported shifting from distressing emotions to states of clarity and resilience. While inducing physical sensations like numbness, chiric sanango enhances social engagement, underscoring its potential as an adjunct in addiction treatment and for overall psychological well-being.
Abstract
The use of traditional medicinal plants in therapeutic settings has gained increasing attention for their potential in mental health and addiction ...
The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?
Psychiatric Research and Clinical Practice – January 14, 2026
Summary
Psilocybin treatments paired with genuine psychotherapy show promise for improving clinical outcomes, as evidenced by a strong therapeutic alliance correlating with better results in 75% of cases. The Compass Psychological Support Model (CPSM) integrates psychoeducation and psychological support through three phases: preparation, administration, and integration. Key principles emphasize trust, present-moment focus, and client autonomy. Emotional breakthroughs during sessions have been linked to a significant effect size of 0.85, highlighting the importance of psychological frameworks in enhancing psilocybin therapy's efficacy and patient outcomes.
Abstract
A key distinction among clinical trials on psilocybin treatments, for example, those targeting depression, has been whether the psilocybin dosing s...
Mindfulness Components and Their Clinical Efficacy: A Critical Review of an Ongoing Debate.
Healthcare (Basel, Switzerland) – January 13, 2026
Summary
For lasting mental health benefits from mindfulness, cognitive and emotional regulation skills like acceptance appear more crucial than meditation alone. Mindfulness programs demonstrate moderate clinical efficacy in reducing anxiety, depression, and stress. However, reported effect sizes are often inflated due to methodological issues. While meditation is key, health education and informal practices also contribute significantly. When assessing its overall impact, mindfulness shows comparable benefits to established treatments like Cognitive Behavioral Therapy, but a balanced understanding is essential for appropriate integration into mental health care.
Abstract
The rapid expansion of mindfulness research has generated both enthusiasm and controversy regarding its actual clinical value. While meditation is ...
Mind the Motion: Feasibility and Effects of a Qigong Intervention on Interoception and Well-Being in Young Adults.
Healthcare (Basel, Switzerland) – January 13, 2026
Summary
A 12-week Qigong program improved psychological well-being among university students. Of 332 young adults who enrolled, 114 completed the contemplative practice, demonstrating consistent improvements in mindfulness, interoception, and emotion regulation. This mind-body intervention, which integrates gentle movements and breathwork, proved highly feasible. It suggests Qigong offers a promising, low-cost path to enhanced mental health for young adults, effectively fostering mind-body awareness and improving various aspects of psychological well-being.
Abstract
Background/Objectives: The present exploratory study evaluates the feasibility and psychological effects of a structured Qigong intervention implem...
5-MeO-DMT Use in Humans: A Scoping Review of Peer-Reviewed Research
OpenAlex – January 08, 2026
Summary
A systematic review identified 533 studies on 5-MeO-DMT, with 33 meeting eligibility criteria. Of these, 15 employed interventional designs, mainly focusing on inhalation methods. Outcomes assessed included cognition, depression, PTSD, and anxiety. Notably, 87% of interventional studies highlighted significant variability in dosing and study design. This highlights the need for more structured clinical trial designs to better understand the pharmacological effects of 5-MeO-DMT on mental health. Future efforts should explore diverse administration routes and incorporate neuroimaging and longitudinal data for comprehensive insights.
Abstract
Clinical trials using 5-MeO-DMT to treat various mental health conditions are currently underway, however research on 5-MeO-DMT use in humans is li...